Antihypertensive Drugs and Cancer Risk

Kidoguchi, Satoshi; Sugano, Naoki; Yokoo, Takashi; Kaneko, Hidehiro; Akazawa, Hiroshi; Mukai, Mikio; Node, Koichi; Yano, Yuichiro; Nishiyama, Akira

doi:10.1093/ajh/hpac066

Cited by 7 publications

(6 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We emphasized the potential mechanisms underlying the association between hypertension and cancer, cancer-related factors that increase blood pressure, antihypertensive drugs and cancer risk, and the importance of interdisciplinary collaboration to address this complex issue. 54 It is crucial to optimize the risk, diagnosis, and management of hypertension in cancer therapy to improve patient outcomes.…”

Section: Discussionmentioning

confidence: 99%

Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Immune checkpoint inhibitors (ICIs) are becoming widely used for novel cancer treatments. Immune-related adverse events, including cardiac toxicity, are frequently observed following immune checkpoint inhibitor (ICI) use. However, little is known regarding the association between ICIs initiation and hypertension in cancer patients. Methods: A systematic literature search was performed using PubMed, EMBASE, Cochrane Library, and Web of Science Core Collection. The risk of hypertension associated with ICI initiation in randomized controlled trials (RCTs) was evaluated. Hypertension was categorized according to the Common Terminology Criteria for Adverse Events. The odds ratios of grades I to V and grades III to V hypertension were calculated using a random-effects meta-analysis. Results: Thirty-two RCTs (n=19 810 cancer patients) were included. At a median follow-up of 36 months, the median overall survival was 15 months in the ICI group. ICI initiation was not significantly associated with hypertension (grades I–V: odds ratio, 1.12 [95% CI, 0.96–1.30]; grades III–V: odds ratio, 0.95 [95% CI, 0.78–1.16]). Additionally, no significant differences in hypertension risk were evident in ICI combination therapies with various drugs, including anti-VEGF (vascular endothelial growth factor) agents. In a subgroup analysis based on clinical setting (placebo RCT versus nonplacebo RCT), there were discrepancies between the results obtained with different methodologies, with patients in the nonplacebo RCTs having higher grades I–V hypertension (I 2 =88.6%, P for heterogeneity=0.003). Conclusions: ICI initiation was not associated with short-term risk of hypertension in cancer patients, and the association was similar regardless of concomitant treatment with other anticancer drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Numerous investigations have assessed the association between antihypertensive drugs and cancer, comprising of randomized controlled studies, basic research, and epidemiological data ( Kidoguchi et al, 2022 ). However, there is currently no relevant study on the relationship between antihypertensive drugs and risk of oral cancer.…”

Section: Discussionmentioning

confidence: 99%

Association between antihypertensive drugs and oral cancer: a drug target Mendelian randomization study

Guo,

Liu,

Sheng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Recent reports have suggested that antihypertensive drugs may play an oncogenic role in common cancers, but it is still uncertain whether this could influence the risk of oral cancer. Through two-sample Mendelian randomization (MR), we sought to assess the causal effect of antihypertensive drugs on oral cancer outcomes.Methods: To proxy the exposure of antihypertensive drugs, we utilized two genetic instruments, including expression quantitative trait loci of drug target genes and genetic variants within or around drug target genes related to blood pressure from genome-wide association studies. Inverse-variance-weighted MR (IVW-MR) and summary-data-based MR (SMR) were employed to compute the instrument effect estimates.Results: It was observed through IVW-MR analysis that there is a positive relationship between KCNH2 (target of beta-adrenoceptor blockers)–mediated blood pressure and oral cancer (odds ratio [OR] = 1.197, 95% confidence interval [CI] = 1.028–1.394). Similarly, SMR analysis demonstrated that a higher expression of KCNH2 (target of beta-adrenoceptor blockers) was linked to a greater risk of oral cancer (OR = 2.223, 95% CI = 1.094–4.516). Both analyses yielded no consistent evidence of other associations.Conclusion: This two-sample MR study proposed a latent causal association between KCNH2 (target of beta-adrenoceptor blockers) inhibition and diminished risk of oral cancer.

show abstract

“…1,[17][18][19] The role of hypertension as a risk factor for tumors was known for some malignancies, such as kidney cancer. 20,21 A myriad of antineoplastic drugs from vascular endothelial growth factor inhibitor antibodies such as bevacizumab, cisplatin, and carfilzomib caused new or worsened hypertension. 9,[22][23][24][25]…”

Section: Bidirectional Relationship Between Cancer and Hypertensionmentioning

confidence: 99%

Effect of Intensive Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors

Li,

Wang,

Jiang

et al. 2024

Hypertension

View full text Add to dashboard Cite

BACKGROUND: To evaluate whether cancer modifies the effect of intensive blood pressure control on major cardiovascular outcomes. METHODS: Using data of the SPRINT (Systolic Blood Pressure Intervention Trial), we compared the risk of the composite outcomes of myocardial infarction, other acute coronary syndromes, stroke, heart failure, and cardiovascular death in patients with and without a history of cancer. Using Cox proportional hazards regression, we tested interactions between history of cancer and intensive blood pressure control on major cardiovascular outcomes. RESULTS: The study included a total of 9336 patients, with a mean age of 67.9±9.4 years, among whom 2066 (22.2%) were cancer survivors. Over a median follow-up of 3.2 years, 561 primary cardiovascular outcomes were observed. Cancer survivors had a similar risk of experiencing the primary outcome compared with patients without cancer after multivariable adjustment (adjusted hazard ratio, 0.94 [95% CI, 0.77–1.15]). Intensive blood pressure control reduced risk of the primary cardiovascular outcome similarly for cancer survivors (hazard ratio, 0.70 [95% CI, 0.51–0.97]) and patients without cancer (HR, 0.76 [95% CI, 0.63–0.93]; P for interaction 0.74). CONCLUSIONS: In SPRINT study, intensive blood pressure treatment reduced the risk of major cardiovascular events in cancer survivors to a similar extent to that of patients without cancer. Cancer history not requiring active treatment in last 2 years should not be an obstacle to intensive treatment of hypertension. This post hoc analysis should be considered as hypothesis-generating and merit further clinical trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01206062.

show abstract

Antihypertensive Drugs and Cancer Risk

Cited by 7 publications

References 119 publications

Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis

Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis

Association between antihypertensive drugs and oral cancer: a drug target Mendelian randomization study

Effect of Intensive Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors

Contact Info

Product

Resources

About